ags

Anti-ENPP3/CD203c Antibody (AGS-16C3F antibody) is a human-derived antibody expressed in CHO cells, targeting ENPP3/CD203c. It features a huIgG1 heavy chain and a huκ light chain with an estimated molecular weight (MW) of 154.04 kDa. For an isotype control, refer to HumanIgG1kappa, Isotype Control.

AGS-16C3F is an antibody-drug conjugate (ADC) targeting ENPP3. It is composed of an Anti-ENPP3/CD203c Antibody linked to MonomethylauristatinF via a linker. AGS-16C3F exhibits antitumor activity and is applicable in research on metastatic renal cell carcinoma (mRCC).

ASG-5ME is a drug-antibody coupling targeting SLC44A4 that shows anti-tumor activity in xenograft models and may be used to study pancreatic and gastric cancer.

Anti-SLC44A4 Antibody (ASG-5ME Antibody) is an antibody that targets SLC44A4, used for synthesizing ADC ASG-5ME.

AGS-67E is a human-derived antibody expressed in CHO cells, targeting TSPAN26/CD37. It possesses a huIgG1 heavy chain and a huκ light chain, with an estimated molecular weight (MW) of 143.44 kDa. For isotype control, refer to HumanIgG2kappa, Isotype Control.

AGS-009 is a humanized monoclonal neutralizing antibody that targets IFN-α. It significantly reduces the number of activated lymphocytes (e.g., CD4+ and CD8+ T cells as well as B cells) in a SIV-infected rhesus monkey model. AGS-009 is applicable to research on autoimmune diseases such as systemic lupus erythematosus (SLE) and HIV infection.

Anti-FLT3 Antibody (AGS62P) is an ADC antibody targeting FLT3 for research in acute myeloid leukemia.

Sirtratumab (also known as AGS15C / Ha15-10ac12) is a human monoclonal antibody targeting SLITRK6. It is used in cancer research, particularly in tumor models with high SLITRK6 expression, to investigate the role of SLITRK6 in tumor growth, proliferation, migration, and other biological processes. As a candidate antibody for ADC development, an antibody–drug conjugate derived from Sirtratumab (Sirtratumab vedotin / AGS15E) has been developed to selectively deliver cytotoxic agents to SLITRK6-positive tumor cells, thereby enhancing targeting specificity.

Sirtratumab vedotin (ASG15-ME) is an antibody-drug conjugate (ADC) that links a SLITRK6-specific human gamma 2 antibody (Igγ2) to the microtubule disruption agent monomethyl auristatin E (MMAE) through a protease-cleavable linker [1].